ABBV Q1 2026 Earnings Analysis

Hey everyone! Before we jump in, we need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

The numbers are impressive, Alex. They hit $2.65 in adjusted earnings per share, which was 7 cents above their guidance midpoint. But what really caught my eye was that revenue growth - 12.4% to $15 billion, beating expectations by $300 million. That's some serious momentum.

Two words: Skyrizi and immunology. Skyrizi alone pulled in $4.5 billion in sales, up over 29% operationally. CEO Robert Michael specifically called out the "momentum in immunology and neuroscience" with both segments gaining market share in growing markets. This isn't just about riding a wave - they're creating it.

That's the million-dollar question, Alex. They're facing new competition, including an oral competitor that launched recently. But Stewart seemed pretty confident during the Q&A, pointing to their head-to-head trials across five different mechanisms in psoriasis, superior durability data, and that convenient quarterly dosing. He even suggested the oral competition might expand the market rather than just steal share.

Exactly. And they're not just defending Skyrizi - they're expanding it. The subcutaneous induction data for Crohn's disease looked impressive. Dr. Roopal Thakkar highlighted that in treatment-naive patients, 61% achieved endoscopic response and 73% achieved clinical remission. Those are some serious numbers.

This is potentially game-changing, Alex. In their platform study, the combination doubled the endoscopic remission rate compared to either drug alone - about 42% of patients at week 24. And remember, this was in severely refractory patients where 82% had failed advanced treatments. Thakkar called it "potentially transformative efficacy."

Their obesity program is heating up. The early data on ABBV-295, their long-acting amylin analog, showed nearly 10% weight loss in just 12 weeks. In a predominantly male, non-obese population, no less. With a 270-hour half-life, they're talking about potential monthly dosing, which could be huge for patient compliance.

What I find strategic is their capital allocation. They announced that $100 billion commitment to U.S. R&D and manufacturing over the next decade, including a $1.4 billion pharmaceutical campus in North Carolina. This isn't just about current products - it's about future manufacturing capacity for immunology, oncology, and obesity therapeutics.

That's a bold statement, Alex. Current consensus has Skyrizi at $33 billion by 2031 and Rinvoq at $16 billion. Michael is essentially saying both will exceed those already substantial estimates. Given their track record and pipeline depth, that confidence seems warranted, but it also raises the bar for execution.

Right, and they've already been active - deals with companies like Remagen for their PD-1 VEGF bispecific antibody. They're not just growing organically; they're strategically acquiring capabilities and assets to maintain their competitive moat.

The main risk I see is execution at scale. They're managing multiple major product launches, complex combination therapies, and significant manufacturing investments simultaneously. Success in biotech often comes down to flawless execution, and they're juggling a lot of balls right now.

Agreed. Overall, this looks like a company hitting its stride just as its previous blockbuster faces biosimilar competition. The timing couldn't be better.

Absolutely. Thanks for tuning in to Beta Finch. We'll be back next time with another AI-powered earnings breakdown!